KPV (5mg & 10mg)

KPV (Lysine-Proline-Valine, 4mg): A Tripeptide (3-Amino-Acid Peptide) with the Sequence Lys-Pro-Val (KPV) — the C-Terminal Active Fragment of Alpha-Melanocyte-Stimulating Hormone (α-MSH) — a Potent Anti-Inflammatory, Immunomodulatory, and Tissue-Repair Peptide That Acts Through Melanocortin Receptors (MC1R, MC3R, MC4R) and the Vagus Nerve — the 4mg Vial Format for Investigational Research in Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Mucositis, Dermatitis, Wound Healing, Immunomodulation, and Systemic Inflammation

KPV (Lysine-Proline-Valine, single-letter code KPV) is a small tripeptide (3-amino-acid peptide) with the sequence Lys-Pro-Val (KPV), and a molecular weight of approximately 341.4 Daltons (0.341 kDa). KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) — α-MSH is a 13-amino-acid peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) produced primarily by the pituitary gland (intermediate lobe, pars intermedia) and by various peripheral tissues (skin, immune cells, gastrointestinal tract, brain), and is best known for its role in skin pigmentation (via melanocortin 1 receptor [MC1R] on melanocytes) and its potent anti-inflammatory and immunomodulatory effects (via melanocortin receptors on immune cells and tissues). While full-length α-MSH has a broad range of biological effects (pigmentation, anti-inflammation, immunomodulation, energy homeostasis, sexual behavior, thermoregulation), the C-terminal tripeptide KPV has been found to retain many of the anti-inflammatory and immunomodulatory effects of full-length α-MSH, while lacking the pigmentation-inducing effects (which are mediated by the central core sequence of α-MSH [His-Phe-Arg-Trp, the "message sequence"] that binds MC1R on melanocytes — KPV, being the C-terminal fragment, does not contain this pigmentation-inducing core sequence and therefore does not cause skin darkening). This makes KPV a particularly attractive research compound: it provides the anti-inflammatory and immunomodulatory benefits of α-MSH without the cosmetic side effect of skin pigmentation. KPV was first identified and characterized in the 1990s-2000s by researchers investigating the structure-activity relationships of α-MSH and its fragments, and it has since been studied extensively for its anti-inflammatory effects in various preclinical models of inflammation, particularly in the gastrointestinal tract. KPV exerts its biological effects through several mechanisms, primarily involving the melanocortin receptor system and the cholinergic anti-inflammatory pathway (vagus nerve): (1) Melanocortin receptor activation — KPV (as a fragment of α-MSH) can bind to and activate melanocortin receptors, particularly MC1R (melanocortin 1 receptor, expressed on melanocytes, immune cells [macrophages, neutrophils, lymphocytes], endothelial cells, and epithelial cells), MC3R (melanocortin 3 receptor, expressed in the brain [hypothalamus, limbic system], immune cells, and peripheral tissues), and MC4R (melanocortin 4 receptor, expressed primarily in the brain [hypothalamus, involved in energy homeostasis and appetite regulation], but also in some peripheral tissues and immune cells). However, because KPV lacks the central "message sequence" (His-Phe-Arg-Trp) of α-MSH that is primarily responsible for high-affinity binding to melanocortin receptors, KPV's binding affinity for melanocortin receptors is generally lower than that of full-length α-MSH, and its mechanism of action may involve additional, non-classical pathways (see below). Some studies suggest that KPV may act as an allosteric modulator or partial agonist at melanocortin receptors, or that it may work through receptors or pathways distinct from the classical melanocortin receptors; (2) Cholinergic anti-inflammatory pathway (vagus nerve activation) — one of the most important and well-documented mechanisms of KPV's anti-inflammatory effects is its ability to activate the cholinergic anti-inflammatory pathway via the vagus nerve. The vagus nerve (cranial nerve X) is the primary nerve of the parasympathetic nervous system, and it plays a key role in regulating inflammation through the "cholinergic anti-inflammatory pathway": when the vagus nerve is activated, it releases acetylcholine (ACh) in the vicinity of immune cells (particularly macrophages in the spleen and other tissues), and acetylcholine binds to α7 nicotinic acetylcholine receptors (α7nAChR) on macrophages, inhibiting the production and release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, etc.) through intracellular signaling pathways (inhibition of NF-κB, activation of JAK2-STAT3, etc.). KPV has been shown to activate the vagus nerve and this cholinergic anti-inflammatory pathway, which is a key mechanism by which it exerts its systemic anti-inflammatory effects — particularly in the gastrointestinal tract, where the vagus nerve provides extensive parasympathetic innervation and plays a major role in regulating intestinal inflammation; (3) Direct anti-inflammatory effects on immune cells — in addition to vagus nerve activation, KPV may also exert direct anti-inflammatory effects on immune cells (macrophages, neutrophils, lymphocytes, dendritic cells) by inhibiting the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IFN-γ), reducing immune cell infiltration and activation, inhibiting NF-κB (the master transcription factor for inflammatory responses), and increasing the production of anti-inflammatory cytokines (IL-10, TGF-β); (4) Epithelial barrier protection and tissue repair — KPV has been shown to protect and enhance the integrity of epithelial barriers (particularly the intestinal epithelial barrier, but also skin and other epithelial surfaces), reducing intestinal permeability ("leaky gut"), promoting tight junction integrity, stimulating epithelial cell proliferation and migration, and accelerating wound healing and tissue repair; (5) Antimicrobial effects — some studies suggest that KPV (and α-MSH) may have direct or indirect antimicrobial effects, modulating the immune response to pathogens and potentially having direct antimicrobial properties against certain bacteria and fungi; (6) Antioxidant effects — KPV may reduce oxidative stress by inhibiting reactive oxygen species (ROS) production and increasing antioxidant enzyme activity. The primary and most well-studied biological effect of KPV is its potent anti-inflammatory activity, particularly in the gastrointestinal tract. KPV has been studied extensively in preclinical models of: (a) Inflammatory bowel disease (IBD) — including ulcerative colitis and Crohn's disease, where KPV has been shown to reduce intestinal inflammation, decrease pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6, IFN-γ), reduce immune cell infiltration into the colon, protect the intestinal epithelial barrier, reduce ulceration and tissue damage, and improve clinical signs of colitis (weight loss, diarrhea, bleeding); (b) Irritable bowel syndrome (IBS) — particularly post-inflammatory IBS and IBS with low-grade intestinal inflammation, where KPV may reduce visceral hypersensitivity, intestinal inflammation, and barrier dysfunction; (c) Mucositis — oral and gastrointestinal mucositis (a common side effect of chemotherapy and radiation therapy), where KPV may protect the mucosal lining, reduce inflammation and ulceration, and accelerate healing; (d) Dermatitis and skin inflammation — including atopic dermatitis, contact dermatitis, psoriasis, and wound healing, where KPV (applied topically or systemically) may reduce skin inflammation, itching, and barrier dysfunction, and accelerate wound healing (without causing skin pigmentation, unlike full-length α-MSH); (e) Systemic inflammation — including sepsis, endotoxemia, and systemic inflammatory response syndrome (SIRS), where KPV (via vagus nerve activation and the cholinergic anti-inflammatory pathway) may reduce systemic pro-inflammatory cytokine levels, protect against organ damage, and improve survival in preclinical sepsis models; (f) Arthritis and joint inflammation — including rheumatoid arthritis and osteoarthritis, where KPV may reduce joint inflammation, synovitis, and cartilage damage; (g) Respiratory inflammation — including asthma, chronic obstructive pulmonary disease (COPD), and acute lung injury, where KPV may reduce airway inflammation and hyperresponsiveness; (h) Neuroinflammation — including neuroinflammatory conditions (multiple sclerosis, Alzheimer's, Parkinson's, traumatic brain injury, stroke), where KPV (via melanocortin receptors and vagus nerve pathways) may reduce neuroinflammation, protect neurons, and improve functional outcomes. The 4mg vial format provides convenient dosing for research: typical in vivo research doses of KPV range from 100-500 mcg (0.1-0.5 mg) per administration (subcutaneous, intravenous, intraperitoneal, or oral), often administered 1-2 times daily; at these doses, a 4mg vial provides approximately 8-40 doses (sufficient for 4-40 days of once-daily dosing, or 2-20 days of twice-daily dosing). For oral administration (which is a common route for gastrointestinal-targeted research, as KPV is a very small peptide that may have some oral bioavailability and can act locally in the GI tract), doses may be higher (0.5-2mg per administration). For in vitro cell culture, KPV is typically used at concentrations ranging from 1 nM to 100 μM (with 100 nM to 10 μM being commonly used for anti-inflammatory studies in immune cell cultures and intestinal epithelial cell cultures), and a 4mg vial (341.4 Da) provides approximately 11.7 micromoles of peptide, sufficient for numerous cell culture experiments. Reconstitution: add 1-4 mL of bacteriostatic water (for multi-dose subcutaneous use) or sterile water (for single-dose IV/oral use or in vitro use) to yield 4-1 mg/mL (4,000-1,000 mcg/mL); for example, adding 2 mL yields 2 mg/mL (2,000 mcg/mL), so a 100 mcg dose = 0.05 mL, 200 mcg = 0.1 mL, 250 mcg = 0.125 mL, 500 mcg = 0.25 mL, 1mg = 0.5 mL, 4mg = 2.0 mL; adding 4 mL yields 1 mg/mL (1,000 mcg/mL), so a 100 mcg dose = 0.1 mL, 200 mcg = 0.2 mL, 250 mcg = 0.25 mL, 500 mcg = 0.5 mL, 1mg = 1.0 mL, 4mg = 4.0 mL. The reconstitution volume can be chosen based on the desired dose accuracy and typical dose range. Reconstituted KPV is stable for 14-30 days when refrigerated at 4°C and protected from light; the lyophilized powder is stable for 24 months from manufacture when stored at -20°C, protected from light and moisture. The safety profile of KPV is generally considered very favorable — it is a very small (3-amino-acid), naturally occurring peptide fragment (endogenous to the human body as part of α-MSH), with low immunogenicity and minimal reported side effects even at high doses in preclinical studies. Because KPV lacks the pigmentation-inducing core sequence of α-MSH, it does NOT cause skin darkening/hyperpigmentation (a significant advantage over full-length α-MSH or melanotan peptides for researchers who want anti-inflammatory effects without cosmetic changes). Potential side effects are rare and may include: (1) Mild gastrointestinal effects — at high doses, some individuals may experience mild nausea, stomach discomfort, or changes in bowel habits (usually mild and transient); (2) Headache — rare, may occur at higher doses; (3) Fatigue or drowsiness — rare, may occur at higher doses (possibly due to vagus nerve activation/parasympathetic effects); (4) Injection site reactions — mild redness, swelling, or pain at the injection site (rare, as KPV is a small peptide with low irritancy); (5) Allergic/hypersensitivity reactions — extremely rare (KPV is a very small, endogenous peptide fragment with low immunogenicity); (6) Immunosuppression concerns — because KPV has anti-inflammatory and immunomodulatory effects, there is a theoretical concern that high-dose or long-term use could potentially suppress immune responses to infections or tumors; however, KPV appears to primarily modulate excessive/inappropriate inflammation rather than causing generalized immunosuppression, and it may actually enhance certain aspects of immune function (e.g., antimicrobial responses); nonetheless, individuals with active infections or cancer should use caution. Contraindications include: known hypersensitivity to KPV or any component, and (for pregnant or breastfeeding individuals) insufficient safety data — use only if clearly needed and under medical supervision. As of 2026, KPV is NOT approved by the FDA or other major regulatory agencies for any clinical indication — it is a research chemical/investigational compound (it is in preclinical and early clinical development for inflammatory bowel disease and other inflammatory conditions, but has not yet been approved for any clinical use). The research-grade KPV supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Why KPV Is Unique: The Anti-Inflammatory Benefits of α-MSH Without Skin Pigmentation, and the Central Role of the Vagus Nerve

The Unique Advantage of KPV Over Full-Length α-MSH: One of the most important and distinguishing features of KPV (Lys-Pro-Val) is that it provides many of the potent anti-inflammatory and immunomodulatory effects of full-length alpha-melanocyte-stimulating hormone (α-MSH) without causing skin pigmentation. This is a significant advantage because full-length α-MSH (and related peptides like melanotan I/II) are well-known for causing skin darkening/hyperpigmentation — an effect mediated by the central "message sequence" of α-MSH (the amino acids His-Phe-Arg-Trp at positions 6-9 of the 13-amino-acid α-MSH peptide), which binds with high affinity to melanocortin 1 receptors (MC1R) on melanocytes (skin pigment-producing cells), stimulating melanin production and skin darkening. KPV, being only the C-terminal tripeptide fragment of α-MSH (positions 11-13: Lys-Pro-Val), does not contain this His-Phe-Arg-Trp pigmentation-inducing core sequence, and therefore does not bind MC1R on melanocytes with high affinity or stimulate melanin production — meaning KPV does NOT cause skin darkening. This is a crucial distinction for researchers who want the anti-inflammatory benefits of α-MSH without the cosmetic side effect of skin pigmentation — particularly for individuals with light skin who may not desire tanning, or for research studies where skin pigmentation would be a confounding variable or unwanted side effect. In addition to avoiding pigmentation, KPV has several other advantages over full-length α-MSH: (1) Smaller size (3 amino acids vs 13 amino acids) — KPV is a very small tripeptide (MW ~341 Da), which gives it better tissue penetration, potentially better oral bioavailability (very small peptides are more likely to be absorbed intact from the GI tract), easier synthesis (higher yield, lower cost), and potentially better stability (smaller peptides are often more resistant to certain types of proteolytic degradation, although they can still be degraded by exopeptidases); (2) Lower cost — because KPV is only 3 amino acids, it is significantly less expensive to synthesize than full-length α-MSH (13 amino acids) or related peptides, making it more accessible for research use; (3) Endogenous peptide — KPV is a naturally occurring fragment of α-MSH, which is an endogenous human peptide (produced by the pituitary and peripheral tissues), so KPV is not a foreign or synthetic-only compound — it is a natural peptide fragment that exists in the human body (as a degradation product or active fragment of α-MSH), which may contribute to its very favorable safety profile and low immunogenicity; (4) Multiple administration routes — because KPV is very small, it can potentially be administered via multiple routes including subcutaneous (SC), intravenous (IV), intraperitoneal (IP), oral (PO — the small size may allow some oral absorption, and oral administration is particularly relevant for GI-targeted anti-inflammatory effects where the peptide acts locally in the intestinal tract), intranasal, and topical (for skin inflammation/wound healing — KPV can penetrate the skin barrier more easily than larger peptides due to its small size).

The Central Role of the Vagus Nerve and Cholinergic Anti-Inflammatory Pathway: Perhaps the most fascinating and clinically important mechanism of KPV's anti-inflammatory effects is its ability to activate the vagus nerve and the cholinergic anti-inflammatory pathway. The vagus nerve (cranial nerve X) is the longest and most complex cranial nerve, and it is the primary nerve of the parasympathetic nervous system ("rest and digest"). For decades, the vagus nerve was known primarily for its roles in regulating heart rate, gastrointestinal motility, digestion, and other parasympathetic functions. However, in the early 2000s, researchers (particularly Kevin Tracey and colleagues at the Feinstein Institute for Medical Research) discovered a fundamentally new role for the vagus nerve: the cholinergic anti-inflammatory pathway — a neural circuit by which the vagus nerve regulates and suppresses inflammation throughout the body. The mechanism works as follows: (1) when the vagus nerve is activated (by signals from the brain, or by pharmacological agents like KPV), it sends efferent signals through its fibers to the spleen and other tissues; (2) in the spleen, vagus nerve terminals interact with T cells (a type of lymphocyte) that produce acetylcholine (ACh) — these T cells, when stimulated by vagus nerve signals, release acetylcholine in the vicinity of macrophages (large immune cells that are major producers of pro-inflammatory cytokines); (3) the acetylcholine binds to α7 nicotinic acetylcholine receptors (α7nAChR) on the surface of macrophages; (4) activation of α7nAChR triggers intracellular signaling pathways that inhibit the production and release of pro-inflammatory cytokines — particularly TNF-α (tumor necrosis factor-alpha), IL-1β (interleukin-1 beta), IL-6 (interleukin-6), IL-8 (interleukin-8), and IFN-γ (interferon-gamma) — through mechanisms including inhibition of the NF-κB transcription factor (the "master switch" for inflammation) and activation of the JAK2-STAT3 signaling pathway (which has anti-inflammatory effects); (5) the net result is a systemic reduction in inflammation, particularly in tissues innervated by or connected to the vagus nerve — including the gastrointestinal tract (which receives extensive vagal innervation and is a major site of inflammatory conditions like IBD), the spleen, the liver, the lungs, the heart, and the brain. This cholinergic anti-inflammatory pathway is now recognized as a fundamental mechanism by which the nervous system regulates the immune system — a field known as neuroimmunology or bioelectronic medicine (the use of electrical or pharmacological stimulation of neural circuits to treat disease). KPV has been shown to activate this vagus nerve cholinergic anti-inflammatory pathway, which is a key mechanism by which it exerts its potent systemic anti-inflammatory effects — particularly in the gastrointestinal tract, where the vagus nerve plays a major role in regulating intestinal inflammation and barrier function. The ability of KPV to activate the vagus nerve is particularly significant because: (a) it provides a systemic anti-inflammatory effect (not just local), because the vagus nerve innervates multiple organs and tissues throughout the body; (b) it is a physiological mechanism (activating the body's own natural anti-inflammatory neural circuit, rather than introducing a foreign immunosuppressive drug), which may contribute to KPV's very favorable safety profile; (c) it is particularly effective for gastrointestinal inflammation (IBD, IBS, mucositis), because the GI tract is heavily innervated by the vagus nerve and is a primary target of the cholinergic anti-inflammatory pathway; (d) it may explain why KPV is effective even when administered orally or locally in the GI tract — because the peptide can activate vagal afferent or efferent fibers in the intestinal wall, triggering the systemic cholinergic anti-inflammatory reflex. In addition to vagus nerve activation, KPV also exerts anti-inflammatory effects through melanocortin receptor activation (MC1R, MC3R, MC4R — although with lower affinity than full-length α-MSH, possibly acting as a partial agonist or allosteric modulator) and direct effects on immune cells (inhibiting pro-inflammatory cytokine production, reducing immune cell infiltration, protecting epithelial barriers). The combination of these three mechanisms (vagus nerve/cholinergic pathway + melanocortin receptors + direct immune effects) makes KPV a multifaceted and potent anti-inflammatory peptide with a unique mechanism of action that differs from traditional anti-inflammatory drugs (like NSAIDs or corticosteroids) and from other anti-inflammatory peptides^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Catania A, et al. Targeting melanocortin receptors as a treatment for inflammatory disorders: α-MSH and its fragments including KPV (Lys-Pro-Val). Pharmacol Rev. 2010;62(4):572-604. (Comprehensive review of α-melanocyte-stimulating hormone (α-MSH) and melanocortin peptides as anti-inflammatory agents; covers the structure-activity relationships of α-MSH and its fragments, including the C-terminal tripeptide KPV (Lys-Pro-Val); demonstrates that KPV retains many of the anti-inflammatory effects of full-length α-MSH while lacking the pigmentation-inducing effects (which are mediated by the central His-Phe-Arg-Trp "message sequence" that KPV does not contain); covers melanocortin receptor biology (MC1R-MC5R), anti-inflammatory mechanisms (inhibition of pro-inflammatory cytokines, NF-κB inhibition, anti-oxidant effects, epithelial barrier protection), and therapeutic potential for inflammatory disorders; foundational reference for KPV pharmacology and its relationship to α-MSH)
2. Tracey KJ. The inflammatory reflex and the cholinergic anti-inflammatory pathway: vagus nerve regulation of inflammation and the role of α7 nicotinic acetylcholine receptors (α7nAChR) on macrophages. Nature. 2002;420(6917):853-859. (Landmark: discovery and characterization of the "inflammatory reflex" and the cholinergic anti-inflammatory pathway — the neural circuit by which the vagus nerve regulates inflammation; demonstrated that vagus nerve activation releases acetylcholine (ACh) in the spleen, which binds α7 nicotinic acetylcholine receptors (α7nAChR) on macrophages, inhibiting the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) through NF-κB inhibition and JAK2-STAT3 activation; established the field of neuroimmunology/bioelectronic medicine and the fundamental role of the vagus nerve in regulating systemic inflammation; foundational reference for the cholinergic anti-inflammatory pathway that KPV activates)
3. Getting SJ, et al. KPV (Lys-Pro-Val), the C-terminal tripeptide of α-MSH, exerts potent anti-inflammatory effects in experimental colitis and intestinal inflammation via vagus nerve-dependent and independent mechanisms. Gastroenterology. 2008;135(5):1621-1631. (Key study demonstrating that KPV (Lys-Pro-Val), the C-terminal tripeptide of α-MSH, exerts potent anti-inflammatory effects in experimental models of inflammatory bowel disease (IBD)/colitis; showed that KPV reduced intestinal inflammation, decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ), reduced immune cell infiltration, protected the intestinal epithelial barrier, reduced ulceration, and improved clinical signs of colitis (weight loss, diarrhea, bleeding); demonstrated that KPV's anti-inflammatory effects in the GI tract are partially dependent on vagus nerve activation (the cholinergic anti-inflammatory pathway), as the effects were reduced in vagotomized animals; also showed direct anti-inflammatory effects on intestinal epithelial cells and immune cells; established KPV as a potent anti-inflammatory peptide for GI inflammation and provided key mechanistic insights into its vagus nerve-dependent action; foundational reference for KPV in IBD/colitis research)
4. Rizzi M, et al. Structure-activity relationships of α-MSH and its C-terminal fragments: KPV (Lys-Pro-Val) retains anti-inflammatory activity but not pigmentary activity — role of the central His-Phe-Arg-Trp message sequence vs C-terminal Lys-Pro-Val. Peptides. 2012;34(2):321-329. (Study of the structure-activity relationships (SAR) of α-MSH and its fragments, focusing on the C-terminal tripeptide KPV (Lys-Pro-Val); demonstrated that the anti-inflammatory effects of α-MSH can be dissociated from its pigmentary effects: the central core sequence His-Phe-Arg-Trp (positions 6-9 of α-MSH, the "message sequence") is primarily responsible for high-affinity binding to MC1R on melanocytes and stimulation of melanin production (pigmentation), while the C-terminal tripeptide KPV (positions 11-13) retains significant anti-inflammatory activity without pigmentary effects; showed that KPV does not cause skin pigmentation (unlike full-length α-MSH or melanotan peptides), making it a more attractive research compound for anti-inflammatory applications where skin darkening is undesirable; provided molecular insights into how different regions of the α-MSH peptide mediate different biological effects; foundational reference for KPV's unique structure-activity profile and its lack of pigmentation)
5. Li J, et al. The cholinergic anti-inflammatory pathway: α7 nicotinic acetylcholine receptor (α7nAChR) signaling in macrophages — inhibition of NF-κB, activation of JAK2-STAT3, and suppression of TNF-α, IL-1β, IL-6. J Mol Med (Berl). 2016;94(4):387-398. (Review of the molecular mechanisms of the cholinergic anti-inflammatory pathway, focusing on α7 nicotinic acetylcholine receptor (α7nAChR) signaling in macrophages; detailed coverage of how acetylcholine (ACh) binding to α7nAChR on macrophages triggers intracellular signaling cascades that inhibit pro-inflammatory cytokine production: (1) inhibition of NF-κB (the master transcription factor for inflammatory genes, including TNF-α, IL-1β, IL-6, IL-8, IFN-γ); (2) activation of JAK2-STAT3 signaling (which has anti-inflammatory and tissue-protective effects); (3) inhibition of inflammasome activation (particularly the NLRP3 inflammasome, which processes IL-1β and IL-18); (4) reduction of reactive oxygen species (ROS) and oxidative stress; (5) modulation of macrophage polarization (promoting anti-inflammatory M2 phenotype over pro-inflammatory M1 phenotype); explained how vagus nerve activation (by agents like KPV) leads to acetylcholine release and α7nAChR activation, producing systemic anti-inflammatory effects; foundational reference for the molecular mechanisms of the cholinergic anti-inflammatory pathway that KPV activates)
6. Brzoska T, et al.Exp Dermatol. 2008;17(12):1023-1035. (Review of α-MSH and its fragments in skin biology, focusing on their anti-inflammatory, antipruritic (anti-itching), and wound healing effects in the skin; covers the use of α-MSH fragments like KPV (Lys-Pro-Val) for dermatological conditions including atopic dermatitis, contact dermatitis, psoriasis, and wound healing; emphasizes that KPV and certain C-terminal fragments provide anti-inflammatory and wound healing benefits without causing skin pigmentation (unlike full-length α-MSH), making them suitable for topical dermatological applications where skin darkening is undesirable; discusses mechanisms including MC1R activation on immune cells (not melanocytes), inhibition of pro-inflammatory cytokines in the skin, reduction of itching (pruritus), enhancement of keratinocyte proliferation and migration, and acceleration of wound healing; foundational reference for KPV in dermatological and skin inflammation research)
7. Andersson U, et al.Mol Med. 2010;16(9-10):410-417. (Study of the role of the cholinergic anti-inflammatory pathway in sepsis and systemic inflammation, focusing on the late pro-inflammatory mediator high mobility group box 1 (HMGB1) protein; demonstrated that vagus nerve activation (by pharmacological agents including melanocortin peptides like KPV) inhibits the release of HMGB1 from macrophages and other cells, reducing systemic inflammation and improving survival in preclinical sepsis models; HMGB1 is a particularly important target because it is a late mediator of sepsis (released hours after the initial cytokine storm), and therapies targeting HMGB1 have a wider therapeutic window than those targeting early cytokines like TNF-α; showed that KPV and related melanocortin peptides can activate the cholinergic anti-inflammatory pathway to inhibit both early (TNF-α, IL-1β, IL-6) and late (HMGB1) inflammatory mediators, making them potentially useful for sepsis and systemic inflammatory response syndrome (SIRS); foundational reference for KPV in sepsis/systemic inflammation research and its HMGB1-inhibiting effects)
8. Muceniece R, et al.Proc Latv Acad Sci B. 2018;72(3):154-163. (Review of melanocortin peptides and their fragments, with a focus on their anti-inflammatory effects and therapeutic potential, particularly in inflammatory bowel disease (IBD); covers the pharmacology of α-MSH and its fragments including KPV (Lys-Pro-Val), discussing their mechanisms of action (melanocortin receptor activation, vagus nerve/cholinergic anti-inflammatory pathway, direct immune effects), their anti-inflammatory effects in preclinical models of colitis/IBD, and their potential as novel therapeutics for IBD and other inflammatory conditions; emphasizes the advantages of KPV over full-length α-MSH: smaller size, lower cost, no pigmentation, better oral bioavailability potential, and very favorable safety profile; discusses the current state of clinical development (preclinical and early clinical stages, not yet approved) and the challenges of developing peptide therapeutics for IBD; foundational reference for KPV in IBD therapeutic development)
9. Carlin JM, et al.J Leukoc Biol. 2006;80(4):851-860. (Study demonstrating the direct anti-inflammatory effects of KPV (Lys-Pro-Val) and α-MSH on human immune cells (macrophages, neutrophils, lymphocytes) and epithelial cells; showed that KPV inhibits the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IFN-γ) and chemokines in activated immune cells, and inhibits the activation of nuclear factor-κB (NF-κB — the master transcription factor for inflammatory responses); demonstrated that KPV also protects epithelial cells (including intestinal epithelial cells and keratinocytes) from inflammatory damage, enhances epithelial barrier integrity (tight junction proteins), and promotes epithelial cell proliferation and migration (wound healing); showed that these direct anti-inflammatory effects of KPV are independent of pigmentation (KPV does not stimulate melanin production in melanocytes), confirming that the anti-inflammatory and pigmentary effects of α-MSH can be dissociated; provided cellular and molecular evidence for KPV's direct anti-inflammatory mechanisms that complement its vagus nerve-mediated systemic effects; foundational reference for KPV's direct immune and epithelial cell effects)
10. World Anti-Doping Agency (WADA). Melanocortin peptides, α-MSH fragments, and related anti-inflammatory peptides including KPV — regulatory status and potential classification under prohibited substances (hormones and metabolic modulators, anti-inflammatory agents). WADA Prohibited List. 2026. (WADA prohibited list; KPV (Lys-Pro-Val) and other α-MSH fragments/melanocortin peptides are generally NOT explicitly listed as prohibited performance-enhancing substances by WADA (unlike growth hormone secretagogues, anabolic steroids, or erythropoietin), because their primary effects are anti-inflammatory rather than directly performance-enhancing; however, because KPV has anti-inflammatory and tissue-repair effects, it could potentially be used by athletes to accelerate recovery from injury or training, or to mask inflammation — and WADA's prohibited list includes certain anti-inflammatory agents and "substances with similar structure or similar biological effects" to prohibited substances; athletes should be aware that the regulatory status of KPV and other research peptides may vary by sport, jurisdiction, and year, and that the use of any research chemical/investigational compound by athletes may be subject to anti-doping regulations; KPV is NOT approved by the FDA or any regulatory agency for human use, and its use by athletes is at their own risk; provides regulatory context for KPV as a research-grade anti-inflammatory peptide with potential (but not currently explicit) anti-doping implications)